The Niemann-Pick C1 (NPC1) protein is a key participant in intracellular sterol trafficking and regulation of cholesterol homeostasis. NPC1 contains a pentahelical region that is evolutionarily related to sterol-sensing domains found in other polytopic proteins involved in sterol interactions or sterol metabolism, including sterol regulatory element-binding protein cleavage-activating protein and hydroxymethylglutaryl-CoA reductase. To gain insight into the role of the sterol-sensing domain of NPC1, we examined the effect of point mutations in the NPC1 sterol-sensing domain on the trafficking of low density lipoprotein-derived cholesterol and sphingolipids. We show that an NPC1 P692S loss of function mutation results in decreased cholesterol delivery to the plasma membrane and endoplasmic reticulum. By contrast, NPC1 proteins carrying a L657F or D787N point mutation, which correspond to the activating SCAP L315F and D443N mutations, respectively, exhibit a gain of function phenotype. Specifically, cell lines expressing the NPC1 L657F or D787N mutations show a nearly 2-fold increase in the rates of low density lipoprotein cholesterol trafficking to the plasma membrane and to the endoplasmic reticulum, and more rapid suppression of sterol regulatory element-binding protein-dependent gene expression. Trafficking of sphingolipids is intact in the D787N and L657F cell lines. Our finding that D787N and L657F are activating NPC1 mutations provide evidence for a conserved mechanism for the sterol-sensing domain among cholesterol homeostatic proteins.
The Niemann-Pick C1 (NPC1) protein is a key participant in intracellular sterol trafficking and regulation of cholesterol homeostasis. NPC1 contains a pentahelical region that is evolutionarily related to sterol-sensing domains found in other polytopic proteins involved in sterol interactions or sterol metabolism, including sterol regulatory element-binding protein cleavage-activating protein and hydroxymethylglutaryl-CoA reductase. To gain insight into the role of the sterol-sensing domain of NPC1, we examined the effect of point mutations in the NPC1 sterol-sensing domain on the trafficking of low density lipoprotein-derived cholesterol and sphingolipids. We show that an NPC1 P692S loss of function mutation results in decreased cholesterol delivery to the plasma membrane and endoplasmic reticulum. By contrast, NPC1 proteins carrying a L657F or D787N point mutation, which correspond to the activating SCAP L315F and D443N mutations, respectively, exhibit a gain of function phenotype. Specifically, cell lines expressing the NPC1 L657F or D787N mutations show a nearly 2-fold increase in the rates of low density lipoprotein cholesterol trafficking to the plasma membrane and to the endoplasmic reticulum, and more rapid suppression of sterol regulatory element-binding protein-dependent gene expression. Trafficking of sphingolipids is intact in the D787N and L657F cell lines. Our finding that D787N and L657F are activating NPC1 mutations provide evidence for a conserved mechanism for the sterol-sensing domain among cholesterol homeostatic proteins.
Niemann-Pick type C (NPC)
1 disease is a fatal, autosomal recessive lipid storage disorder characterized by lysosomal cholesterol accumulation and defective regulation of cellular cholesterol homeostasis (1, 2) . 95% of NPC disease cases are caused by mutations in the NPC1 gene, which encodes a 1278-amino acid polytopic protein containing 13 transmembrane domains (3) . The region of the NPC1 protein encompassing transmembrane domains 3-7 (amino acids 615-797) is evolutionarily related to sterol-sensing domains found in five other polytopic proteins that are involved in sterol interactions or sterol metabolism (4) . The NPC1 sterol-sensing domain shares ϳ30% identity with the sterol-sensing domains of HMG-CoA reductase, SREBP cleavageactivating protein (SCAP), NPC1-L1, and Patched (5) . A carboxyl-terminal dileucine motif targets NPC1 to the endocytic pathway, where it localizes to a late endosomal compartment that is LAMP-2-positive, Rab7-positive, and cation-independent mannose-6-P receptor-negative (6 -8) .
The NPC1 protein is a key participant in intracellular sterol trafficking. Cells harboring inactivating mutations in NPC1 are defective in the delivery of newly hydrolyzed low density lipoprotein (LDL) cholesterol to the plasma membrane (PM), demonstrate impaired rates of esterification of LDL cholesterol, and accumulate unesterified cholesterol in an aberrant late endosomal/lysosomal compartment (9 -11) . Conversely, overexpression of NPC1 results in dose-dependent increases in delivery of endosomal cholesterol to the PM and in esterification of LDL cholesterol (10) . The sterol trafficking defect in cells that have inactivating mutations in NPC1 further results in delayed down-regulation of the LDL receptor and de novo cholesterol biosynthesis (12) (13) (14) . These sterol regulatory defects correlate with a deficiency in LDL cholesterol-stimulated production of 25-hydroxycholesterol (25-HC) and 27-hydroxycholesterol (27-HC) (14) . These enzymatically generated oxysterols reduce the cellular cholesterol burden by suppressing sterol regulatory element-binding protein (SREBP)-dependent gene expression and by serving as ligands for liver X receptors. Treatment of NPC1 mutant fibroblasts with either 25-HC or 27-HC corrects the sterol homeostatic defects and mobilizes accumulated unesterified cholesterol (14, 15) . Taken together, these findings suggest that NPC1 regulates cellular cholesterol homeostasis by channeling excess LDL cholesterol to sites of oxysterol synthesis (2, 14) .
Cholesterol that traffics as bulk cargo in the endocytic pathway also plays a role in modulating late endosomal function. Cholesterol overload delays retroendocytic clearance of fluidphase markers and alters the rate of cholesterol movement along this pathway (6) . Whereas the mechanism by which cholesterol regulates NPC1 function is not known, recent studies of homologous proteins (HMG-CoA reductase, SCAP, and Patched) indicate that the sterol-sensing domain is involved in regulating sterol-dependent protein-protein interactions. HMG-CoA reductase catalyzes the rate-limiting step in de novo cholesterol biosynthesis, and SCAP regulates the activity of the SREBP transcription factors. In both HMG-CoA reductase and SCAP, the sterol-sensing domains modulate sterol-dependent interactions with the resident endoplasmic reticulum (ER) proteins, Insig-1 and Insig-2 (16). Sterol-stimulated binding of the Insig proteins to HMG-CoA reductase results in its ubiquitination and subsequent proteosomal degradation. Similarly, Insig proteins bind to SCAP in the presence of cholesterol, leading to retention of SCAP-SREBP complexes in the ER, thereby preventing proteolytic processing of SREBPs and expression of genes involved in cholesterol uptake and biosynthesis (17, 18) . The role of the sterol-sensing domain of Patched, a morphogen that binds members of the hedgehog family of signaling proteins and regulates the activity of the Smoothened seven-pass membrane protein, has not been fully elucidated, but recent studies suggest that it may function to regulate the vesicular trafficking of Patched between the PM and endosomes (19, 20) . Cells harboring the Y298C, L315F, or D443N point mutations in SCAP demonstrate a sterol-resistant phenotype, characterized by cholesterol overload because of constitutive processing of SREBP (21) . Furthermore, the Y298C and D443N SCAP mutants are resistant to conformational changes normally induced by cholesterol, and the Y298C mutant fails to bind the Insig-1 and Insig-2 retention proteins (21, 22) . Similarly, the corresponding mutation in Patched (D584N) produces a dominant negative protein and prevents the down-regulation of Smoothened activity (19) . In HMG-CoA reductase, mutations in the YIYF motif of the sterol-sensing domain, which correspond to the SCAP Y298C substitution, confer resistance to sterol-mediated degradation (16) .
The role of the sterol-sensing domain of NPC1 in intracellular cholesterol trafficking is not yet understood. Expression of the P691S point mutant in human NPC1 (P692S in the murine ortholog) results in an NPC1 protein that is properly targeted to the late endosome, but fails to correct the sterol trafficking defect (23, 24) . The P692S loss of function mutant also exhibits severely reduced labeling with a photoactivatable cholesterol (25) . These findings indicate that an intact sterol-sensing domain is required for cholesterol binding and NPC1 protein function. In the present study, we examined the effects of point mutations in the NPC1 sterol-sensing domain on the trafficking of LDL-derived cholesterol and sphingolipids. We provide evidence that NPC1 proteins carrying point mutations corresponding to the activating SCAP L315F and D443N mutations are fully functional, and exhibit increased rates of LDL cholesterol trafficking to the PM and ER. These data demonstrate the functional importance of the NPC1 sterol-sensing domain in regulation of LDL cholesterol trafficking in mammalian cells, and are consistent with the hypothesis that this domain of NPC1 functions in a manner analogous to the homologous domains in SCAP and HMG-CoA reductase. Plasmids-A modified ⌬U3 retroviral construct (26) containing a NotI site in its multiple cloning site was used as a backbone for the ⌬U3mNPC1-WT-CFP, ⌬U3mNPC1-P692S-CFP, and ⌬U3mNPC1-Y-635C-CFP constructs. The NotI/BglII fragment (5.2 kB) was isolated from this construct and ligated to a BglII/KasI fragment (880 bp) from ⌬U3mNPC1 and a KasI/NotI fragment (4 kB) from either pECFP-N3-mNPC1-6xHis WT or pECFP-N3-mNPC1-6xHis P692S (kindly provided by M. Scott). To make the ⌬U3mNPC1-Y635C-CFP construct, a 6.2-kb NotI/PflMI fragment from the modified ⌬U3 retroviral construct was isolated and ligated to a 4.1-kb fragment from the pECFPmNPC1-6xHis Y635C construct (kindly provided by M. Scott). ⌬U3m-NPC1-D787N-CFP and ⌬U3mNPC1-L657F-CFP constructs were generated using the QuikChange XL Site-directed Mutagenesis Kit (Stratagene), using the ⌬U3mNPC1-WT-CFP construct as a template. The primers used to introduce the D787N mutation were: 5Ј-GTGAG-CCTGTTGGGGTTAAATATTAAGAGGCAAGAGAAAAACC-3Ј and 5Ј-GGTTTTTCTCTTGCCTCTTAATATTTAACCCCAACAGGCTCA-3Ј. The primers used to introduce the L657F mutation were: 5Ј-GGTGGA-TTCTAAGATCTCGTTCGGCATTGCGGGGATCCTG-3Ј and 5Ј-CAGG-ATCCCCGCAATGCCGAACGAGATCTTAGAATCCACC-3Ј. Locations of the mutations are indicated by the nucleotides in boldface type. The presence of the P692S, Y635C, D787N, and L657F mutations in the expression constructs were confirmed by ABI Prism automated sequencing.
EXPERIMENTAL PROCEDURES

Materials
Cell Lines-Chinese hamster ovary-K1 (CHO-K1) cells (CRL-9618) were obtained from ATCC. M12 cells are mutant CHO-K1 cells that contain a deletion of the NPC1 locus, and CHO/NPC1 cells are CHO-K1 cells that overexpress human NPC1 (10) . To generate the M12/NPC1-CFP and CHO/NPC1-CFP cell lines, CHO-K1 and M12 cells were infected with retrovirus prepared by transient transfection of 293GPG packaging cells with the ⌬U3mNPC1-CFP constructs as previously described (26) . To isolate clonal cell lines, the retrovirally infected M12 cells were plated at limiting dilution and colonies were subjected to two rounds of screening. Colonies were first screened by filipin staining (described under "Fluorescence Microscopy") and by cyan fluorescent protein (CFP) fluorescence. Colonies were also screened for expression of mNPC1 by Western blotting of TNET lysates using an antibody that recognizes CFP (described under "Protein Preparation and Western Blot Analysis"). Colonies with similar expression levels of the wild type (WT), P692S, D787N, and L657F constructs were selected for further analysis.
Cell Culture-Cells were maintained in monolayer culture at 37°C with 5% CO 2 . All CHO-derived cell lines were maintained in medium A (1:1 Dulbecco's modified Eagle's medium/Ham's F-12, 5% (v/v) fetal calf serum, 2 mM glutamine, 50 units/ml penicillin, 50 g/ml streptomycin). Medium B consists of medium A in which fetal calf serum has been replaced with 5% (v/v) lipoprotein-deficient fetal calf serum. 293GPG cells were cultured as described previously (26) .
Preparation of Reconstituted LDL-LDL labeled with [ 3 H]cholesteryl linoleate (CL) ([ 3 H]CL-LDL) was prepared with a specific activity of 34,000 cpm/nmol of total cholesteryl linoleate as described (27) .
Protein Preparation and Western Blot Analysis-Detergent lysates were prepared by washing cell monolayers twice with phosphate-buffered saline (PBS). Cells were then scraped in 400 l of TNET ϩ (1% Triton X-100, 0.15 M NaCl, 50 mM Tris, pH 8.0, 2 mM EDTA, 1ϫ Complete protease inhibitor mixture, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, 1 g/ml pepstatin A, 1 g/ml leupeptin, 25 g/ml ALLN, 2.4 g/ml Pefabloc) and incubated on ice for 10 min. Nuclei were pelleted by centrifugation at 1000 ϫ g at 4°C, and supernatant was transferred to a new tube. Proteins in these TNET lysates were quantified using the Bicinchoninic Acid (BCA) Protein Assay Kit (Pierce). Non-boiled samples were resolved by SDS-PAGE under reducing conditions. Proteins were transferred onto nitrocellulose (0.45 mm; Schleicher & Schuell) with a semi-dry electroblotter (Owl Scientific). Western blot analysis of CFP expression was performed using an affinity purified mouse monoclonal antibody raised against full-length GFP (BD Biosciences) at a dilution of 1:1000 and a peroxidase-conjugated donkey anti-mouse IgG at 0.04 g/ml. Detection was performed by chemiluminescence using Renaissance reagents (PerkinElmer Life Sciences).
Fluorescence Microscopy-On day 0, cells were plated at 2. 3 H]cholesteryl oleate was quantified as described above. LDL Receptor Activity Assay-LDL receptor activity was determined as described previously (14) . On day 0, cells were plated at 7 ϫ 10 4 cells/35-mm well in medium A. On day 1, cells were refed medium B. On day 2, cells were incubated with DiI-LDL (6 g/ml) for 1 h and the mean fluoresence of 10,000 cells was measured by flow cytometetry using a FACScan (BD Biosciences).
Cholesterol Efflux Assay-Efflux studies were performed as previously described (29) with minor modifications. On day 0, cells were plated in triplicate (2.5 ϫ 10 4 cells/35-mm well) in medium A. On day 1, the cells were washed three times with PBS and refed medium B. On day 3, cells were refed medium B containing 15 mM HEPES, pH 7.4, and incubated at 4°C for 30 min. Cells were subsequently refed medium B containing 15 mM HEPES, pH 7.4, and 0 -40 g/ml [
3 H]CL-LDL and incubated at 16 -18°C for 4 h. Cells were then washed three times with PBS, refed medium B, and incubated at 37°C for 2 h, followed by a 10-min incubation with medium B containing 4% CD at 37°C. Media was collected, cells were washed three times with Tris-buffered saline at 4°C, and cells were extracted with 0. Quantification of HMG-CoA Synthase Gene Expression-On day 0, cells were plated at 1 ϫ 10 5 cells/60-mm dish) in medium A. On day 1, cells were washed twice with PBS and refed medium B. On day 3, cells were refed medium in the presence or absence of 40 g/ml LDL. After 4 h cells were harvested, total RNA isolated using TRIzol reagent (Invitrogen), and reverse transcribed to cDNA using SuperScriptII RNase H Ϫ reverse transcriptase and random heximer primers (Invitrogen). cDNA was then amplified for 40 PCR cycles using SYBR Green PCR master mixture (Applied Biosystems) and template-specific primers (50 nM) in an ABI Prism 7500 sequence detector. Primer sequences for hamster HMG-CoA synthase (forward, 5Ј-CCTGGGTCACTTCCTT-TGAATG-3Ј; reverse 5Ј-GATCTCAAGGGCAACGATTCC-3Ј) and ␤-actin (forward, 5Ј-GGCTCCCAGCACCATGAA-3Ј; reverse 5Ј-GCCAC-CGATCCACACAGAGT-3Ј) were kindly provided by David Russell (University of Texas, Southwestern). Relative quantification of gene expression was performed using the comparative threshold (C T ) method as described by the manufacturer. Changes in mRNA expression level were calculated following normalization to ␤-actin expression.
Intracellular Trafficking of BODIPY LacCer-Sphingolipid trafficking assays were performed as described previously (30) . Cells were plated on coverslips at 2 ϫ 10 4 cells/150-mm well on day 0. On day 1, cells were washed three times with DMEM, and pulsed for 45 min at 37°C, 5% CO 2 with 5 M BODIPY LacCer, 1% fetal bovine serum in DMEM. Cells were washed three times with 1% fetal bovine serum in DMEM, followed by a 60-min chase in 1% fetal bovine serum in DMEM at 37°C, 5% CO 2 . Cells were then washed twice with DMEM containing 15 mM HEPES, pH 7.4, and BODIPY was back-exchanged from the cell surface by six successive 10-min incubations at 10°C in 5% fatty acid free BSA and 15 mM HEPES in DMEM. Following back exchange, cells were fixed as described under "Fluorescence Microscopy." Cells were permeabilized and blocked with 0.2% saponin and 0.5% fatty acid-free BSA in PBS for 30 min. Cells were then stained with 50 g/ml filipin in 0.5% fatty acid-free BSA in PBS for 30 min. For co-staining with Texas Red-LcH, coverslips were then incubated with 15 g/ml Texas Red-LcH in PBS containing 50 g/ml filipin and 0.5% fatty acid-free BSA for 45 min at 37°C. Coverslips were subsequently washed three times with PBS, mounted, and examined by fluorescence microscopy as described above. The following additional filter sets (Chroma) were used: for BODIPY, excitation filter 500/20 nm, emission filter 535/30 nm; for Texas Red-LcH, emission filter 546/12, excitation filter 590 nm long pass.
Statistics-All results are expressed as mean Ϯ S.E. The statistical significance of differences in mean values was determined by single factor analysis of variance. Data shown are representative of at least two similar experiments.
RESULTS
Generation of Cell Lines Expressing NPC1-CFP Fusion Proteins-
The sterol-sensing domain of NPC1 shares 30% identity with homologous regions of HMG-CoA reductase, SCAP, and Patched (Fig. 1) . To investigate the function of this domain, we introduced the following point mutations into NPC1: P692S, Y635C, D787N, and L657F. Based on earlier studies, we anticipated that the P692S substitution would result in NPC1 loss of function (23, 24) . On the other hand, we hypothesized that the Y635C, D787N, and L657F substitutions, which involve conserved residues in the sterol-sensing domain (see asterisks in Fig. 1 ) and induce a sterol-resistant phenotype in HMG-CoA reductase and SCAP, would result in NPC1 gain of function. For these studies, a retroviral expression system was used to establish cell lines expressing CFP-tagged WT and mutant versions of NPC1 in the NPC1-null M12 CHO cell line (10) . ⌬U3 retroviral constructs were transfected into 293GPG packaging cells to produce virus encoding WT and mutant NPC1 (26) . This virus was used to infect both WT CHO and NPC1-null M12 cells to generate populations of cells stably expressing the NPC1-CFP constructs at various levels. These populations were used for initial fluorescence microscopy studies (Figs. 2  and 3) .
Mutations in the SSD of NPC1 Do Not Induce Dominant Inhibitory Effects-Because it is not known whether NPC1 carries out its cellular functions through a mechanism involving protein-protein interactions, it was first important to determine whether any of the NPC1-CFP constructs could induce dominant inhibitory effects in WT cells. Populations of WT CHO cells transduced with the NPC1-WT-CFP and mutant NPC1-CFP constructs were stained with filipin to visualize unesterified cholesterol, and examined by fluorescence microscopy. CHO cells express endogenous NPC1 and were therefore an appropriate background to use for these experiments (10, 11, 31) . As shown in Fig. 2 , the enlarged, filipin-positive structures present in NPC1-null CHO cells are not observed in the WT CHO cells, cells transduced with the NPC1-WT-CFP, or cells transduced with any of the four mutant NPC1-CFP constructs. In cells expressing the NPC1-CFP constructs, filipin staining is observed at the cell periphery and in a Golgi-like pattern similar to the pattern observed in non-transduced cells. NPC1-CFP appears primarily in a granular pattern, consistent the established late endosomal distribution of endogenous NPC1 in WT CHO cells (8, 10) . These results indicate that both WT and mutant forms of NPC1 are appropriately localized when expressed in WT CHO cells and that none of these constructs is capable of inducing the NPC phenotype in the presence of a functional copy of NPC1.
NPC1-D787N-CFP and NPC1-L657F-CFP Can Correct Free Cholesterol Accumulation in NPC1-null Cells-Further fluores-
cence microscopy studies were carried out to determine whether the sterol-sensing domain mutants were capable of correcting the accumulation of free cholesterol (i.e. the NPC phenotype) in NPC1-null M12 cells. As expected, NPC1-WT-CFP, but not NPC1-P692S-CFP, was able to complement the mutant phenotype of the NPC1-null cells (Fig. 3) . Expression of either the NPC1-D787N-CFP or NPC1-L657F-CFP putative gain of function mutants complemented NPC1-null cells as well, indicating that introduction of these substitutions does not diminish NPC1 function. Expression of the putative gain of function NPC1-Y635C-CFP resulted in only partial complementation of the NPC phenotype. This may be related to lower levels of expression of NPC1-Y635C-CFP in WT CHO and NPC1-null M12 cells, as compared with the other sterol-sensing domain mutants (data not shown), or to reduced levels of mature NPC1 glycoprotein (23) . In NPC1-null M12 cells transduced with the WT, D787N, or L657F constructs, NPC1-CFP again localized primarily to granular structures. In NPC1-null M12 cells transduced with the P692S construct, by contrast, NPC1-CFP localized to the limiting membrane of cholesterol-rich, filipin-positive structures (Figs. 3  and 7) , similar to the distribution of NPC1 observed following pharmacologic induction of the NPC phenotype (10). This staining pattern is not observed in WT CHO cells transduced with the P692S construct (see Fig. 2 ).
Isolation of Clonal Cell Lines Expressing NPC1-CFP Mutant
Proteins-Clonal cell lines were isolated from the NPC1-null cell populations transduced with the WT and mutant NPC1 constructs by plating at limiting dilution. The clonal cell lines were used for all subsequent fluorescence microscopy studies and for all biochemical studies. The clones were screened for expression of CFP by fluorescence microscopy and by Western blotting of cell lysates using an affinity purified mouse monoclonal antibody to GFP. Clones with similar levels of CFP expression and predominantly endosomal CFP staining patterns (WT, D787N, and L657F cell lines) or NPC1 staining of the periphery of filipinpositive compartments (P692S cell lines) were selected for further study. Because of the low level of stable expression of the NPC1-Y635C-CFP construct, as compared with the other sterolsensing domain constructs, the Y635C substitution was not examined further in the context of clonal cell lines. As determined by densitometry of four independent Western blots, the clonal cell lines transduced with the P692S, D787N, and L657F constructs express CFP-tagged NPC1 proteins at levels that do not differ significantly from levels of NPC1-CFP expression in the cell line transduced with NPC1-WT-CFP (see Fig. 4 ). The clonal cell lines will be referred to hereafter as null/WT, null/P692S, null/D787N, and null/L657F.
Delivery of LDL Cholesterol from Endosomes to the Plasma Membrane Is Increased in the Null/D787N and Null/L657F Cell
Lines-To characterize the effects of the sterol-sensing domain mutations on trafficking of endocytosed LDL cholesterol, we first examined rates of delivery of LDL cholesterol to the PM cholesterol pool. For these studies, delivery of newly hydrolyzed LDL cholesterol to the PM was monitored by efflux to CD, an efficient extracellular cholesterol acceptor. Cells were loaded with [ 3 H]CL-LDL at 16 -18°C. At this temperature, there is no significant hydrolysis of LDL cholesteryl esters and trafficking of free cholesterol from late endosomes is prevented (32) . Brief incubations with CD enabled sampling of cholesterol predominantly associated with the PM pool, rather than with intracellular membranes (29, 33) . As expected, the null/P692S cells had significantly impaired delivery of LDL cholesterol to the PM, similar to that reported previously for NPC1-null cells (Fig. 5, A and B) (9 -11) . In contrast, null/D787N and null/L657F cells, as compared with null/WT cells, demonstrated significantly increased rates of delivery of cholesterol to the PM at both 20 g/ml LDL (1.3-1.4-fold) and 40 g/ml LDL (1.6 -1.9-fold). The increased delivery of cholesterol to the PM is comparable with the 1.6-fold increase observed in NPC1-overexpressing CHO cells (10) . To exclude the possibility that the enhanced cholesterol efflux in the null/D787N and null/L657F cells was because of increased accessibility of PM cholesterol to CD, null/WT, null/ D787N, and null/L657F cells were labeled to equilibrium with [ 3 H]cholesterol, and incubated with CD under the same conditions used for the efflux assay. We found that the CD-accessible cholesterol pool in null/D787N and null/L657F cells was decreased by 23 and 20%, respectively, as compared with the null/WT cells (Fig. 5C ). Differences in cholesterol esterification rates are unlikely to have contributed to the reduced CDaccessible cholesterol pool in null/D787N and null/L657F cells because Ͻ0.05% of cell-associated [ 3 H]cholesterol was esterified under these experimental conditions (not shown). Thus, the increased rate of cholesterol delivery to the PM in the null/D787N and null/L657F cells cannot be attributed to an increase in CD-accessible cholesterol. Because NPC1 is known to participate in delivery of LDL cholesterol from endosomes to the PM, the sterol trafficking phenotype of the D787N and L657F mutants is consistent with a gain of function phenotype.
Rates of Cholesterol Esterification Are Increased in the D787N and L657F Mutants-To determine the effects of the sterol-sensing domain mutations on trafficking of LDL cholesterol to the ER, we compared rates of LDL-stimulated esterification in the null/WT, null/P692S, null/D787N, and null/L657F clonal cell lines. In WT cells, uptake of LDL cholesterol expands the cellular cholesterol pool and activates acyl-CoA:cholesterol O-acyltransferase, which catalyzes the esterification of both de novo synthesized and LDL-derived cholesterol in the ER (34 (Fig. 6A) . In contrast, cholesterol esterification rates in null/D787N and null/L657F cells are increased by up to 2-and 1.7-fold, respectively, as compared with WT. Similar LDL cholesterol esterification results were obtained using independently isolated clonal cell lines (not shown). The increased rates of cholesterol esterification in the null/D787N and null/L657F cells are specific for LDL cholesterol because rates of 25-HC-stimulated cholesterol esterification do not differ significantly between null/WT and null/D787N or null/ L657F cells (Fig. 6B) . To exclude the possibility that increased LDL cholesterol esterification in null/D787N and null/L657F cells was because of increased LDL uptake, we measured LDL receptor activity in these cell lines. We found no difference in the rate of uptake in null/WT versus null/ D787N and null/L657F cells (Fig. 6C) . The increased LDL receptor activity in the null/P692S cells reflects the impaired suppression of SREBP-dependent gene expression that is characteristic of the NPC1-null phenotype (12) (13) (14) . To examine the consequence of increased cholesterol delivery to the ER in the null/D787N and null/L657F cells, we measured expression of the sterol-regulated gene, HMG-CoA synthase, in response to LDL cholesterol. We find that null/D787N and null/L657F cells show a greater suppression of HMG-CoA synthase expression than null/WT cells, consistent with the more rapid delivery of LDL cholesterol to ER membranes in these mutants (Fig. 6D) . Taken together, the esterification and gene expression data are consistent with the previous observation of increased LDL cholesterol esterification rates in CHO cells overexpressing WT NPC1 (10) , and suggest that the D787N and L657F substitutions in the sterol-sensing domain confer NPC1 gain of function.
Sphingolipid Trafficking Is Intact in the D787N and L657F Mutants-The trafficking of BODIPY-LacCer, a fluorescent sphingolipid analog, was examined by fluorescence microscopy to assess the trafficking of sphingolipids in the clonal cell lines expressing the NPC1 sterol-sensing domain mutants. It has been established previously that in pulse-chase experiments, BODIPY LacCer localizes to the aberrant late endosomal "NPC compartment" in skin fibroblasts derived from NPC patients, but localizes to the Golgi complex in skin fibroblasts derived from non-affected individuals (30) . Thus, we expected that in   FIG. 4. Expression of WT, P692S, D787N, and L657F NPC1 in clonal NPC1-null cell lines. A, populations of NPC1-null CHO cells expressing NPC1-WT-CFP, NPC1-P692S-CFP, NPC1-D787N-CFP, or NPC1-L657F-CFP were plated at limiting dilution and individual colonies were screened for the expression of NPC1-CFP by Western blotting using an ␣-GFP monoclonal antibody that recognizes CFP. Clonal cell lines having similar levels of CFP expression were chosen for use in subsequent biochemical experiments. B, CFP expression levels in these clonal cell lines were evaluated by densitometry. Values are mean expression levels from four independent Western blots Ϯ S.E. and have been normalized to expression of NPC1-WT-CFP. p ϭ not significant for WT versus mutant cell lines. similar pulse-chase experiments in the null/WT cells, the BODIPY LacCer would localize to the Golgi complex, whereas in the null/P692S cells, the BODIPY LacCer would localize to the filipin-and CFP-positive late endosomal compartments (see Fig. 3 ). Indeed, in the null/WT cells, the BODIPY-LacCer predominantly co-localized with the Texas Red-lentil lectin (LcH) Golgi marker in a crescentic, perinuclear staining pattern (Fig. 7) . Filipin staining revealed localization of cholesterol primarily to the PM and Golgi in the null/WT cells, and NPC1-WT-CFP appeared in a punctate, late endosomal pattern (not shown). By comparison, in the null/P692S cells, BODIPY LacCer co-localized with NPC1-P692S-CFP to the filipin-positive aberrant NPC compartment. The Texas RedLcH Golgi marker (which has a carbohydrate specificity of ␣-mannose and other carbohydrate moieties) also appeared to partially co-localize to this compartment (not shown), consistent with the hypothesis that there is an accumulation of glycolipids, as well as cholesterol, in the NPC compartment. Interestingly, in the null/D787N and null/L657F cells, BODIPY LacCer co-localized with the Texas Red-LcH Golgi marker, in a pattern that was indistinguishable from staining in null/WT cells. These findings indicate that sphingolipid trafficking is intact in the L657F-and D787N-expressing cells.
DISCUSSION
In this study we examined the function of the NPC1 sterolsensing domain in trafficking of LDL-derived cholesterol and sphingolipids. NPC1 proteins harboring P692S, D787N, or L657F mutations in this domain are expressed and appropriately localize to late endosomes. The P692S substitution results in a loss of function phenotype, characterized by failure to traffic LDL cholesterol from late endosomes, and accumulation of free cholesterol and sphingolipids in an aberrant endosomal compartment to which NPC1-P692S also localizes. By contrast, expression of NPC1 proteins with D787N or L657F substitutions, which correspond to activating mutations in the sterolsensing domains of SCAP and HMG-CoA reductase, results in increased delivery of endocytosed LDL cholesterol to the PM and ER. Targeting of sphingolipids to the Golgi is intact in cell lines expressing the D787N or L657F mutations. The gain of function sterol trafficking phenotype induced by the D787N and L657F mutations provides evidence for a conserved sterolsensing domain mechanism among these evolutionarily related cholesterol homeostatic proteins.
Structure-function studies of the NPC1 protein have shown previously that an intact sterol-sensing domain is required for NPC1 function. The NPC1 P692S mutant expressed in NPC1-null cells is unable to mobilize lysosomal free cholesterol or stimulate late endosomal vesicular trafficking (23, 24) . Our results with the NPC1 P692S mutant showing markedly impaired delivery of LDL cholesterol to the PM and the ER are consistent with these findings. Although this proline is invariant among the NPC1, SCAP, HMG-CoA reductase, and Patched proteins (Fig. 1) , it is not known whether the role this residue is conserved with respect to the sterol-sensing domain mechanism, because the effect of the corresponding mutation has not been reported in other sterol-sensing domain-containing proteins. However, the recent demonstration that NPC1-P692S fails to label with a photoactivatable cholesterol analog (25) indicates that Pro-692 is critical either for direct binding of cholesterol or for proper conformation of the pentahelical sterol-sensing domain to facilitate interaction with cholesterol. To date, examination of putative activating mutations in NPC1 in mammalian cells have focused on the Y635C mutation, which corresponds to the Y298C mutation in SCAP. In previous studies, expression of NPC1-Y635C in NPC1-null cells either failed to mobilize cholesterol from the NPC compartment, or resulted in only partial complementation of the mutant phenotype (23, 24) . More recently, Ohgami et al. demonstrated that introduction of the Y635C substitution abolished labeling of NPC1 with a photoactivatable cholesterol analog, although the trafficking function of NPC1-Y635C was not examined in this study (25) . The low levels of expression of the Y635C mutation and reliance on a complementation assay that is well suited for identification of loss of function mutations, but not activating mutations (23) , may have limited the ability to detect a possible gain of function phenotype for the Y635C mutation. Likewise, in this study we found that NPC1-Y635C is poorly expressed in comparison to the WT protein, thus confounding evaluation of the consequences of this mutation on sterol trafficking.
In the present study, we characterized the effect of the D787N and L657F substitutions, which correspond to the D443N and L315F activating mutations in SCAP, on NPC1 function. Using quantitative sterol trafficking assays, we show for the first time that the D787N and L657F substitutions result in a sterol trafficking-related gain of function phenotype. As compared with cells expressing similar levels of WT NPC1, the D787N and L657F mutants exhibit an ϳ1.6 -1.9-fold increase in the rate of delivery of endosomal cholesterol to the PM and up to 2-and 1.7-fold increases, respectively, in the rate of LDL-stimulated cholesterol esterification, indicative of enhanced NPC1 function. Nearly identical increases in sterol trafficking rates have been observed in CHO cell lines with 10 -15-fold overexpression of WT NPC1 (10) . Additionally, we show that sphingolipid trafficking is intact in the gain of function mutants. Whether the D787N and L657F substitutions also represent activating mutations with respect to sphingolipid trafficking could not be determined on the basis of the qualitative BODIPY-LacCer trafficking assay used in our study. Together with the demonstration that NPC1 binds a cholesterol analog (25) , our findings suggest that the NPC1 sterol-sensing domain functions in a fashion similar to the homologous region in SCAP.
Our results clearly suggest a regulatory role for the NPC1 sterol-sensing domain in intracellular movement of LDL cholesterol cargo in CHO cells. Interestingly, mutagenesis studies of the sterol-sensing domain of the NPC1 yeast ortholog, Ncr1p, have suggested a role for this region in cellular sphingolipid trafficking (35) . In yeast, expression of the Y718D mutant, which corresponds to the mammalian SCAP D443N mutation, resulted in redistribution of PM-derived sphingolipids to the vacuole and other subcellular compartments, although no alterations in sterol metabolism were observed in this mutant. This contrasts with our finding that expression of the corresponding D787N mutation in NPC1 leads to increased rates of sterol trafficking and does not inhibit sphingolipid trafficking in CHO cells. There are several possible explanations for these divergent findings. Significant differences exist between yeast and multicellular organisms with respect to the trafficking and metabolism of sterols. First, unlike mammalian cells, which obtain cholesterol through uptake of lipoproteins, budding yeast do not take up exogenous sterol during aerobic growth. In addition, yeast utilize ergosterol rather than cholesterol to meet their membrane requirements. Second, in yeast membrane sterol appears to traffic directly to the ER, by-passing the vacuole. This contrasts with the itinerary for cholesterol in mammalian cells, in which lipoprotein-associated cholesterol is internalized by receptor-mediated endocytosis and is trafficked to late endosome/lysosomes. Third, deletion of Ncr1p in yeast indicates that this protein is not required for endocytic transport and sterol metabolism in yeast, because unlike in mammalian cells, such a deletion does not promote sterol accumulation in the vacuole (35, 36) . However, when Ncr1p is expressed in NPC1-null CHO cells, it is able to suppress the mutant phenotype, indicating that the yeast ortholog is competent with respect to sterol trafficking (35) . Whether expression of WT Ncr1p, which possesses a tyrosine at position 718 rather than the invariant aspartic acid residue found in the homologous regions of NPC1, SCAP, and HMG-CoA reductase, or the Ncr1p Y718D mutant would result in a sterolrelated gain of function phenotype in CHO cells remains to be determined. It may be that the distinct yeast and mammalian phenotypes resulting from sterol-sensing domain mutations reflect differences in cellular sterol metabolism rather than intrinsic differences in the function of the NPC1 protein orthologs.
Several lines of evidence suggest a conserved function for the sterol-sensing domain among NPC1, SCAP, and HMG-CoA reductase. First, this domain shares 30% identity and is topologically identical among these cholesterol homeostatic pro- teins (5) . Second, overexpression of the sterol-sensing domain of SCAP prevents sterol-mediated degradation of HMG-CoA reductase, implying that both proteins compete for binding to the Insig proteins (37) . Likewise, overexpression of NPC1 results in resistance to sterol-mediated suppression of gene expression, possibly by interfering with binding of SCAP to its retention protein (10) . Third, together with previous studies, our results demonstrate that introduction of mutations at conserved residues in the sterol-sensing domains of NPC1, SCAP, and HMG-CoA reductase confers gain of function phenotypes with respect to cholesterol metabolism.
Our findings support the following model for the role of NPC1 in regulation of cellular cholesterol trafficking. In the setting of lipoprotein deprivation, NPC1 participates in basal movement of lipid cargo from the late endosome. As cholesterol content in endosomal membranes increases, for example, in response to LDL cholesterol loading, NPC1 may bind cholesterol and/or undergo a conformational change that induces binding to a putative Insig-like protein, analogous to the interaction between SCAP and the ER resident Insig proteins. Binding of NPC1 could, therefore, prevent movement of lipid cargo out of late endosomes. The observation that cellular cholesterol enrichment retards retroendocytic clearance of fluid-phase markers provides support for cholesterol-dependent inhibition of NPC1 function (6) . The L657F and D787N mutations may confer a gain of function phenotype by inhibiting sterol-dependent binding of NPC1 to the putative Insig-like protein, allowing constitutive trafficking of NPC1 with its lipid cargo. Alternatively, the gain of function mutations may prevent sterol-mediated ubiquitination and degradation of NPC1, similar to the mechanism demonstrated for the HMG-CoA reductase gain of function mutants.
